Cost-Effectiveness of Fidaxomicin for Clostridium difficile Treatment

被引：2
|
作者：
Simon, Matthew S. [1 ,2 ]
机构：
[1] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA
[2] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY 10065 USA
来源：
CLINICAL INFECTIOUS DISEASES | 2014年 / 58卷 / 04期
关键词：
VANCOMYCIN; INFECTION; CANCER;
D O I：
10.1093/cid/cit772
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF FIDAXOMICIN FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION (CDI) IN SWEDEN
    Van Engen, A.
    Lie, X.
    Noren, T.
    Nordling, S.
    Norgaard, K.
    VALUE IN HEALTH, 2014, 17 (07) : A673 - A674
  • [2] Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan
    Okumura, Hiroyuki
    Ueyama, Maki
    Shoji, Shingo
    English, Marci
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2020, 26 (06) : 611 - 618
  • [3] COST-EFFECTIVENESS ANALYSIS OF FIDAXOMICIN FOR CLOSTRIDIUM DIFFICILE INFECTION IN JAPAN
    Okumura, H.
    Ueyama, M.
    Shoji, S.
    English, M.
    VALUE IN HEALTH, 2019, 22 : S200 - S200
  • [4] COST-EFFECTIVENESS OF FIDAXOMICIN THERAPY FOR CLOSTRIDIUM DIFFICILE INFECTION IN HUNGARY
    Brodszky, V
    Strbak, B.
    Baji, P.
    Pentek, M.
    Gulacsi, L.
    VALUE IN HEALTH, 2014, 17 (07) : A675 - A675
  • [5] Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection
    Nathwani, Dilip
    Cornely, Oliver A.
    Van Engen, Anke K.
    Odufowora-Sita, Olatunji
    Retsa, Peny
    Odeyemi, Isaac A. O.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (11) : 2901 - 2912
  • [6] COST-EFFECTIVENESS ANALYSIS OF FIDAXOMICIN VERSUS ORAL VANCOMYCIN FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION IN EGYPT
    Hossam, M.
    Elsisi, G.
    VALUE IN HEALTH, 2016, 19 (07) : A513 - A513
  • [7] A COMPARISON OF THE COST-EFFECTIVENESS OF FIDAXOMICIN, METRONIDAZOLE, AND VANCOMYCIN, IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASE
    Madkour, N.
    Bounthavong, M.
    Hsu, D., I
    VALUE IN HEALTH, 2012, 15 (04) : A138 - A139
  • [8] Cost-effectiveness of fidaxomicin for the treatment of severe Clostridium difficile infection in hospitalized patients in North America.
    Bott, Quinn
    Rice, Libbi
    Oh, John
    Sinha, Veejaye
    Boyer, Nohemie
    PHARMACOTHERAPY, 2012, 32 (10): : E292 - E292
  • [9] COST-EFFECTIVENESS OF FIDAXOMICIN VERSUS VANCOMYCIN AND METRONIDAZOLE IN PATIENTS WITH CLOSTRIDIUM DIFFICILE INFECTION IN SPAIN
    Watt, M.
    de Nigris, E.
    McCrea, C.
    VALUE IN HEALTH, 2017, 20 (09) : A784 - A784
  • [10] Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France
    Watt, Maureen
    Dinh, Aur Elien
    Le Monnier, Alban
    Tilleul, Patrick
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (07) : 678 - 686
12345